Efficacy and Safety of Rhus verniciflua Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Efficacy and Safety of Rhus verniciflua Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
复制标题
DOI：
10.1159/000327306
复制
发表时间：
2011-01-01
影响因子：
--
通讯作者：
Eo, Wan Kyu
中科院分区：
文献类型：
--
作者：
Cheon, Seong Ha;Kim, Kyung Seok;Eo, Wan Kyu
背景：晚期非小细胞肺癌（NSCLC）的全身治疗具有适度的生存获益，但毒性较高。漆树是一种古老的传统药物，用于治疗癌症。我们研究了去除变应原的RVS提取物（aRVS）延长一线或二线化疗失败的NSCLC患者生存期的有效性和安全性。患者和方法：我们回顾了2006年6月至2009年6月在韩国Mx mu综合癌症中心接受aRVS治疗的40例既往接受过治疗的晚期NSCLC患者的病历。本研究的主要目的是评估总生存期。次要目的包括评估疾病控制率、无进展生存期和aRVS治疗的安全性。结果：中位生存期为8.4个月，1年生存率为40%。疾病控制率63.6%，中位无进展生存期3.9个月。体能状态更好的腺癌患者在总生存期方面的结局更有利。aRVS治疗的毒性可以忽略不计，最常见的药物相关不良事件是轻度上腹痛和皮肤瘙痒。无血液学毒性。结论：生存数据和良好的耐受性水平表明aRVS治疗在既往接受过治疗的晚期NSCLC患者中的潜力。aRVS治疗可能是化疗不可行或拒绝化疗的患者的可行替代方案。
Background: Systemic treatments for advanced non-small cell lung cancer (NSCLC) have modest survival benefits but high toxicity. Rhus verniciflua Stokes (RVS), the lacquer tree, is an ancient traditional medicine being used for the treatment of cancer. We investigated the efficacy and safety of allergen-removed RVS extract (aRVS) for the prolongation of survival in NSCLC after the failure of first-line or second-line chemotherapy. Patients and Methods: We reviewed the medical records of 40 patients who were treated with aRVS for previously treated, advanced NSCLC at the Mx mu Integrative Cancer Center, Korea, between June 2006 and June 2009. The primary objective of this study was to assess overall survival. Secondary objectives included assessments of disease control rates, progression-free survival, and the safety of aRVS treatment. Results: The median survival time was 8.4 months with a 1-year survival of 40%. The disease control rate was 63.6%, and the median progression-free survival interval was 3.9 months. Patients who had better performance status and adenocarcinoma experienced more favorable outcomes in terms of overall survival. Toxicities in aRVS treatment were negligible, with the most common drug-related adverse events being mild epigastric pain and itching skin. Hematologic toxicity was absent. Conclusions: Survival data and favorable levels of tolerability suggest the potential of aRVS treatment in previously treated patients with advanced NSCLC. Treatment with aRVS might be a viable alternative in patients for whom chemotherapy is not feasible, or who refuse chemotherapy.